Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Praluent Coverage: Being First May Not Matter As Payers Await Repatha

Executive Summary

The pricing advantage that might have been available to Praluent as first-in-class is undercut by the fact that it only has about a month’s lead time over the competition.

Advertisement

Related Content

Priority Review Voucher Expansion Could Be Bad, Program Creator Says
Preferred Rivals: Express Scripts Covers Both Repatha And Praluent
Sanofi's Praluent And Amgen's Repatha Now Set For Battle In Europe, US
Repatha Performance Contracting: Sweetening The Pot For Payers
Amgen’s Repatha To Launch Next Week; Narrow Indication Mirrors Rival Praluent
PCSK9 Sponsors May See Opportunity In Off-Label Promotion Court Case
CVS Health Seeks Return To LDL Treatment Targets To Control PCSK9s
Regeneron/Sanofi Offer Free Praluent Samples To Counter Slow Coverage
CVS Continues Preferred Status For Harvoni Over Viekira Pak
Praluent Launch Brings Clinical Practice Challenges

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057039

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel